INTRODUCTION {#S1}
============

Preclinical studies of glioblastoma suggest that regulatory T cells (Tregs) are pivotal for promoting tumor immunosuppression ([@R15]; [@R33]; [@R45]). While previous research has established that Tregs accumulate in CNS malignancies and contribute to immunosuppression ([@R8]; [@R13]; [@R33]; [@R34]; [@R43], [@R44]), the mechanisms by which they thrive in the hypoxic ([@R12]) and nutrient competitive ([@R32]) tumor microenvironment (TME) is not well known. Hypoxic regions are prevalent in CNS tissues and increase with the grade of malignancy ([@R41]), with high-grade gliomas having more regions under chronic hypoxia than lower grade tumors ([@R30]). Therefore, the response to hypoxia may play essential roles in T cell function in glioblastoma.

The prototypical effector of the hypoxic response, hypoxiainducible factor 1α (HIF-1α), is highly active in glioblastoma patients ([@R30]). Furthermore, HIF-1α has been previously identified to correlate positively with the grade, invasion, and progression of glioma ([@R14]; [@R49]). HIF-1α has pleiotropic effects, with wide-ranging effects on angiogenesis ([@R25]), glycolysis ([@R38]), and cell survival under reduced oxygen conditions ([@R39]). Other studies have demonstrated that HIF-1α regulates lipid uptake, which is a potent survival mechanism for tumors ([@R4]). These studies suggest that HIF-1α may endow Tregs with metabolic properties that allow them to endure within the tumor.

The effect of hypoxia on Treg function is conflicting. [@R11] demonstrated that the canonical hypoxia sensor, HIF-1α, negatively regulates Foxp3 expression while promoting TH17 differentiation. Other studies have also lent credence to the Treg-inhibitory actions of HIF-1α ([@R20]; [@R21]). However, other studies have shown that HIF-1α positively affects Treg function ([@R3]; [@R9]) and plays a role in their suppressive function in tumors ([@R47]). This dichotomous nature reflects a complicated role of HIF-1α in immunosuppression, which may provide critical insight into how these cells function. Furthermore, it is unknown how HIF-1α mechanistically leads to enhanced or diminished Treg function within tumors.

HIF-1α inhibits mitochondrial function to prevent oxidative stress from killing cells in oxygen-restricted environments ([@R28]). However, the exact interplay between HIF-1α and the metabolic choice of Tregs is unknown. Interestingly, a recent study has shown that Tregs will utilize lipid metabolism to thrive in poor glucose environments ([@R37]), suggesting that lipid metabolism may be responsible for their survival within tumors. The metabolic properties of Tregs *in vivo* are still a highly contentious topic. While no scientific consensus exists ([@R35]), a constant among studies is that catabolic ([@R22]), mitochondria-driven oxidative phosphorylation ([@R1]; [@R2]) is critical for Treg functionality. The metabolic choices of Tregs in the context of glioma are unknown and may provide novel avenues to enhance immunotherapy.

Herein, utilizing an animal model with Treg-specific ablation of HIF-1α, we reveal that hypoxia promotes the migration of Tregs at the expense of their suppressive function. Under hypoxia, the suppressive function of Tregs is maintained by the lipid uptake and/or oxidation program, which is critical to Treg function both *in vitro* and *in vivo*. These findings resolve the discrepancies in the role of HIF-1α in Tregs, proving that it promotes migration over suppression.

RESULTS {#S2}
=======

Ablation of HIF-1α in Tregs Causes Enhanced Mitochondrial Metabolism {#S3}
--------------------------------------------------------------------

We first crossed Foxp3-YFP-CRE mice to HIF-1α Flox mice to generate a Treg-specific deletion of HIF-1α (termed hereinafter as HIF-1α \[knockout\] KO) to probe the role of this canonical hypoxic sensor to both glycolytic and oxidative phosphorylation (OXPHOS)-driven Treg metabolism. We first sought to understand the mitochondrial metabolic choices Tregs make under hypoxia and how the deficiency of HIF-1α regulates this process in [Figure 1](#F1){ref-type="fig"}. HIF-1α WT (Foxp3-YFP-CRE mice used as wild-type \[WT\] throughout the paper) or HIF-1α KO Tregs were FACS (fluorescence-activated cell sorting) sorted, expanded, and incubated in 21% (normoxia) or 1% (hypoxia) oxygen (O~2~) overnight before a mitochondrial stress test was performed utilizing an extracellular flux analyzer. Palmitate was added as an initial injection, because previous work has shown that Tregs may utilize exogenous fatty acid (FA) uptake for their stability and/or function ([@R6]; [@R34]). Surprisingly, not only did HIF-1α KO Tregs have a higher basal oxygen consumption rate (OCR), maximal OCR, and ATP-linked respiration than control Tregs under normoxia, but they also maintained the same phenotype, even under extreme hypoxia ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). Importantly, under conditions of hypoxia, HIF-1α WT Tregs upregulated OCR with palmitate injection (−0.75 ± 3 versus 6 ± 4 pmol of O~2~ per minute in normoxia versus hypoxia, respectively), while HIF-1α KO Tregs had no change in palmitate-induced OCR, despite having a generally higher amount of palmitate-induced OCR.

Bulk metabolomics data confirmed enhanced citrate, malate, and fumarate with a concomitant decrease in lactate within HIF-1α KO Tregs, compared to HIF-1α WT Tregs, under hypoxia ([Figure S1A](#SD1){ref-type="supplementary-material"}) but not normoxia ([Figure S1B](#SD1){ref-type="supplementary-material"}). However, freshly sorted Tregs from spleens of both HIF-1α WT and HIF-1α KO tumor-bearing mice did not show any significant changes in metabolite content, suggesting that the TME drives metabolic change in Tregs ([Figure S2](#SD1){ref-type="supplementary-material"}). In summation, these data indicate that HIF-1α restricts the mitochondrial metabolism of glucose by Tregs under hypoxia. As we saw a significant increase in palmitate-induced OCR by Tregs under hypoxia, the data suggest that, under hypoxia (like conditions within the TME), Tregs may utilize lipids to perform their metabolic functions. As the mitochondrion is considered to be the central regulator of the immunosuppressive capabilities of Tregs ([@R16]), we next sought to understand how specific ablation of HIF-1α influenced Treg function.

Deletion of HIF-1α Enhances Treg-Mediated Immunosuppression under Hypoxia {#S4}
-------------------------------------------------------------------------

To understand how ablation of HIF-1α influences canonical Treg function, we sorted and expanded Tregs and performed a series of T cell suppressor assays with the same pool of CD8^+^ T cells as responders in [Figure 2](#F2){ref-type="fig"}. There was no change in the suppressive function of Tregs under 21% O~2~ ([Figure 2A](#F2){ref-type="fig"}). Surprisingly, under conditions of hypoxia, HIF-1α KO Tregs were significantly enhanced in their ability to suppress T cell proliferation ([Figure 2B](#F2){ref-type="fig"}). At Treg:CD8 ratios of 1:1, 1:2, and 1:4, the total proliferation of CD8^+^ T cells was dramatically inhibited (p \< 0.001) by HIF-1α KO Tregs, which was also reflected by the reduced CD8^+^ T cell expansion index ([Figure 2B](#F2){ref-type="fig"}, right). As hypoxic signaling is known to upregulate glycolysis by shuttling pyruvate away from the mitochondria to produce more lactate ([@R40]), it is possible that HIF1α KO Tregs are shuttling more glucose into the mitochondria to enhance their suppressive function in hypoxia. Therefore, we attempted to rescue improved Treg suppression by an inhibitor of pyruvate import into the mitochondria, UK5099 ([@R7]). Pre-treatment of HIF-1α KO Tregs with UK5099 (10 μM) abrogated the enhanced suppression of HIF-1α KO Tregs under hypoxia, as measured by CD8^+^ T cell expansion index ([Figure 2C](#F2){ref-type="fig"}). We also treated HIF-1α WT Tregs with dichloroacetate (DCA), a PDK1 inhibitor that promotes mitochondrial function over glycolysis ([@R48]), to mimic the effects of HIF-1α KO ([Figure 2D](#F2){ref-type="fig"}). Tregs pretreated with DCA were significantly better at suppressing T cell proliferation than HIF-1α WT Tregs. These results suggest that HIF-1α restricts glucose oxidation, which stymies Treg immunosuppression. We next sought to dissect the role that lipid OXPHOS has on Treg function and its relevance to Treg metabolism in brain tumors. Furthermore, we sought to understand whether HIF-1α plays a role in these metabolic decisions.

Inhibition of Lipid Uptake and/or Oxidation Prevents Treg Immunosuppressive Capabilities {#S5}
----------------------------------------------------------------------------------------

*In vitro* inhibition of fatty acid oxidation (FAO) with Etomoxir (Eto) (also recently shown to induce oxidative stress in T cells; [@R36]), enhanced the relative Treg abundance of CD3-stimulated splenocytes and also enhanced Treg abundance under Treg-inducing conditions (+transforming growth factor β1 \[+TGF-β1\]) ([Figure S3A](#SD1){ref-type="supplementary-material"}), which is in contrast to previous studies ([@R31]). However, treatment with the irreversible inhibitor of fatty acid transport, sulfo-N-succinimidyl oleate (SSO) ([@R26]), resulted in a significant inhibition in the relative abundance of Tregs. However, there was a consistent change in the expression of many suppressive markers by sorted and expanded Tregs ([Figure 3A](#F3){ref-type="fig"}). In particular, both Eto and SSO treatment significantly inhibit Granzyme B, CD39, and NRP1 expression by Tregs (p \< 0.001). These results suggest that free fatty acids (FFAs) may be needed for the generation of immune suppression within tumors.

As inhibition of lipid uptake and/or oxidation perturbs proteins important to Treg functionality, we determined whether this influenced Treg suppressive abilities ([Figures 3B](#F3){ref-type="fig"}--[3G](#F3){ref-type="fig"}). Expanded Tregs maintained at least 95% of their Foxp3^+^ expression after 48 h of treatment with both inhibitors (which is comparable to controls), suggesting that inhibition of lipid oxidation (Eto) ([Figure 3B](#F3){ref-type="fig"}) or palmitate uptake (SSO) ([Figure 3E](#F3){ref-type="fig"}) does not affect the stability of Foxp3. Pre-treatment with either drug did not affect Treg viability ([Figure S3B](#SD1){ref-type="supplementary-material"}). Inhibitor pre-treated Tregs were extensively washed and co-cultured at different ratios with proliferation-dye-labeled CD8^+^ T cells for 72 h ([Figures 3C](#F3){ref-type="fig"}, [3D](#F3){ref-type="fig"}, [3F](#F3){ref-type="fig"}, and [3G](#F3){ref-type="fig"}). Both treatments resulted in an approximately 2-fold reduction of Treg-mediated suppression at most ratios tested. The results show that Treg-mediated immunosuppression is enforced by lipid uptake and oxidation. We performed these assays under hypoxia, with both HIF1α WT and HIF-1α KO Tregs to understand the importance of HIF-1α signaling on lipid dependence by Tregs ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}). Importantly, the ability of HIF-1α KO Tregs to suppress T cell expansion was unaffected by pre-treatment with either Eto or SSO. This suggests that HIF-1α promotes reliance on FFA by Tregs for the promotion of immunosuppression.

Inhibition of Lipid Metabolism Influences the Mitochondrial Function of Tregs *In Vitro* {#S6}
----------------------------------------------------------------------------------------

We next sought to understand how perturbations in lipid metabolism affect the mitochondrial function of Tregs and how HIF-1α may be regulating this. Pre-treatment of Tregs with Eto decreased maximal respiration of both HIF-1α WT and HIF-1α KO Tregs under normoxia, with no significant changes in basal OCR or ATP-linked respiration ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}). However, under hypoxia, HIF-1α WT Tregs were significantly more affected by Eto treatment than HIF-1α KO Tregs: the basal OCR of only HIF-1α WT Tregs was changed only under hypoxia (84 ± 10 versus 66 ± 10 pmol of O~2~ per minute in control versus Eto-treated Tregs, respectively), and their maximal OCR was more significantly affected than that of HIF-1α KO Tregs ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}) (70% ± 10% reduction in HIF-1α WT and 30% ± 3% in HIF-1α KO Tregs, p \< 0.0027). Of note, Eto pre-treatment increased palmitate-induced OCR in both groups, suggesting that inhibition of lipid oxidation promotes its own subsequent import.

As an alternative approach, we performed the same assays using SSO ([Figure S4](#SD1){ref-type="supplementary-material"}). SSO treatment had minimal effects on mitochondrial metabolism, with the interesting exception that treatment with SSO abolished the increase in palmitate-induced OCR in HIF-1α KO Tregs under both normoxia and hypoxia (p \< 0.001) but not in HIF-1α WT Tregs. As HIF-1α is known to shuttle exogenous FFA into lipid droplets (and away from the mitochondria), enhanced mitochondrial consumption of palmitate by HIF-1α KO Tregs under hypoxia fits with our current knowledge ([@R4]). The results of these experiments suggest that Tregs may utilize lipid metabolism for mitochondrial function under hypoxia, so we next sought to understand the contribution of lipid metabolism to Treg-mediated immunosuppression.

Tregs Prefer Fatty Acid Uptake within Brain Tumors {#S7}
--------------------------------------------------

To determine the metabolic preferences of T cell subsets within the glioma microenvironment, we implanted Foxp3-YFP mice intracranially with the murine GL-261 glioblastoma tumor model and, after 2 weeks of tumor engraftment, performed flow-cytometric analysis on infiltrating T cells ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). Differences in the percentage of cells taking up the quantum-dot 605 (Qdot605)-conjugated palmitic acid biosensor ([@R34]) and the mean fluorescence intensity (MFI) of uptake ([Figure 4C](#F4){ref-type="fig"}) reveal that Tregs uptake dramatically more fatty acid in comparison to both CD8^+^ and CD4^+^ conventional T cells (\*\*\*p \< 0.001). These observations are consistent with our previous results ([@R34]). As glucose uptake can provide alternative fuel for mitochondrial metabolism, we also examined the T cell uptake of glucose using a fluorescent glucose analog (2-NBDG) ([@R51]). 2-NBDG uptake showed a relatively low amount of glucose uptake by all T cell subsets (2%--8%); effector CD4^+^ T cells had the highest percentage of cells taking up glucose (\*p \< 0.05), while Tregs had the highest MFI of 2-NBDG (\*p \< 0.05) ([Figure 4D](#F4){ref-type="fig"}).

While glucose uptake is variable across T cell subsets, the dramatic increase in lipid uptake by Tregs highlights the potential utilization of FFA by Tregs within the TME. Interestingly, analysis of interstitial non-esterified FFA was 3.2-fold higher within the tumor-bearing hemisphere, as compared to the hemisphere without tumor ([Figure 4E](#F4){ref-type="fig"}). The results of these experiments suggest that Tregs may be preferentially utilizing fatty acid uptake and/or oxidation for metabolism in the TME and that the prerequisite substrates are abundant.

FFA uptake from the extracellular environment is known to be mediated by specific fatty acid transporters ([@R17]). We sought to determine the expression of fatty acid transporters on T cell subsets within the tumor tissue, as previous work has shown that Tregs prefer exogenous FA for their metabolic needs ([@R6]). Examination of all three established surface fatty acid transporters, CD36, SLC27A1, and SLC27A4 ([@R17]), revealed a higher percentage of Treg cells expressing fatty acid transporters on the cell surface compared to other T cell subsets. As shown in [Figure 4F](#F4){ref-type="fig"}, Tregs are enriched in the surface expression of CD36, as compared to CD4^+^Foxp3^−^ and CD8^+^ T cell populations, but was not significant in the periphery. [Figure 4F](#F4){ref-type="fig"} shows that the SLC27A1 also was enriched in tumoral Tregs. There is no change in the expression of SLC27A4, suggesting specific surface fatty acid transporter upregulation in the tumor. While all T cells had an upregulation of fatty acid transporters in the brain, Tregs had proportionally more expression, suggesting that they are more sensitive to FA metabolic alteration.

Inhibition of Lipid Oxidation Prevents Immunosuppression in a Murine Model of Glioblastoma {#S8}
------------------------------------------------------------------------------------------

Eto has been previously shown to enhance animal survival in an immunocompetent animal model of glioma ([@R27]). Our data showed no influence on the viability or metabolic uptake of any glioma line tested ([Figure S5](#SD1){ref-type="supplementary-material"}). Thus, we determined whether Eto treatment inhibited immunosuppression of mice harboring brain tumors. As demonstrated in [Figure 5A](#F5){ref-type="fig"}, C57BL/6 mice had a significant increase in survival (\*\*p \< 0.01), with a median survival of 20 and 25 days in control versus intracranial Eto treatment, respectively. In Rag-1 KO mice, which are deficient in T and B cells, there was no significant change in survival, and both groups had a median survival of 22 days ([Figure 5A](#F5){ref-type="fig"}, right). In [Figure 5B](#F5){ref-type="fig"}, Eto-treated groups had a favorable increase in both CD4:Treg and CD8:Treg ratios, as compared to control tumor subsets, which is predictive of therapeutic efficacy ([@R10]). Eto treatment caused a significant decrease in tumor Tregs compared to the control group (\*\*p \< 0.01). These results suggest that Eto treatment has an impact on the microenvironment by inhibition of immunosuppression.

If the significant target of fatty acid oxidation inhibition is on the adaptive immune compartment, then targeting fatty acid oxidation in the periphery may yield results similar to those for intracranial treatment. To test the possibility that peripheral inhibition of fatty acid oxidation enhances animal survival, we injected Eto peripherally every day into tumor-bearing mice, starting 5 days after tumor implantation. As demonstrated in [Figure 5C](#F5){ref-type="fig"}, HIF-1α WT mice had a significant increase in survival (\*\*p \< 0.01) in groups treated intraperitoneally (i.p.) with Eto versus control groups. [Figure 5D](#F5){ref-type="fig"} shows that the Eto-treated groups had a favorable increase in both CD4:Treg and CD8:Treg ratios, \*\*p \< 0.01 and \*p \< 0.05, respectively. The total Treg number is decreased in the Eto-treated group compared to the control group (p \< 0.09) as well as the percentage of CD4^+^Foxp3^+^ T cells. These results suggest that Eto treatment has an impact on systemic immunity against glioma. Lastly, peripheral Eto treatment in HIF1α KO mice bearing tumors had no change in Treg recruitment ([Figure S6A](#SD1){ref-type="supplementary-material"}).

HIF-1α Promotes Glycolysis, Enhancing Treg Migratory Capabilities {#S9}
-----------------------------------------------------------------

As we saw that HIF-1α KO is potentially shuttling more pyruvate into the mitochondria under hypoxia ([Figure 2C](#F2){ref-type="fig"})---and, thus, away from lactic acid production---we measured extracellular acidification induced by hypoxia ([Figure 6](#F6){ref-type="fig"}). HIF-1α WT Tregs had a significantly increased extracellular acidification rate (ECAR) under hypoxia (49 ± 2 mpH/min versus 66 ± 4 mpH/min in normoxia versus hypoxia, respectively). Interestingly, not only did HIF-1α KO Tregs have a lower ECAR compared to controls under normoxia (49 ± 2 mpH/min versus 26 ± 1 mpH/min in HIF-1α WT versus HIF-1α KO Tregs, respectively), but also the ECAR was unaffected by hypoxia (26 ± 1 mpH/min versus 26 ± 2 mpH/min in normoxia versus hypoxia, respectively) ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). Treatment of Tregs with oligomycin reveals the maximal glycolytic capacity of these cells, which highlights a permanent decrease in the glycolytic metabolism in HIF-1α KO Tregs (p \< 0.001) ([Figure 6B](#F6){ref-type="fig"}, right). qPCR of two central regulators of glycolytic metabolism PDK1 and LDHA were upregulated by 4- and 2-fold, respectively, under hypoxia treatment. This effect was abolished in HIF-1α KO Tregs ([Figure 6C](#F6){ref-type="fig"}). Critically, pretreatment of Tregs with the PDK1 inhibitor DCA induced significant decreases in both basal and maximal ECAR ([Figure 6D](#F6){ref-type="fig"}), with a concomitant increase in basal and maximal OCR ([Figure 6E](#F6){ref-type="fig"}), mimicking the effects of HIF-1α deficiency on Treg metabolism.

A recent study highlighted the need for glycolysis in the migratory capabilities of Tregs ([@R24]). To address the migratory capabilities of Tregs, we sorted and expanded HIF-1α KO Tregs and HIF-1α WT Tregs *in vitro* before performing overnight Transwell migration assays ([Figure 6F](#F6){ref-type="fig"}). HIF-1α KO Tregs were significantly stymied in their migration to both a glioma-produced Treg-chemotactic cytokine CCL22 ([@R23])(88.5 ± 2.1 HIF-1α WT versus 44 ± 1.2 HIF-1α KO; p ⩽ 0.001) or cultured GL-261 (83 ± 4.8 HIF-1α WT versus 47.9 ± 6.8 HIF-1α KO; p ⩽ 0.001). Pre-treatment of Eto had no effect on the *in vitro* migration of HIF-1α WT or HIF-1α KO Tregs ([Figure S6B](#SD1){ref-type="supplementary-material"}). Critically, extracellular flux analysis showed that pulsing with CCL22 induces significantly more glycolytic metabolism in HIF-1α WT Tregs as compared to HIF-1α KO Tregs ([Figure 6G](#F6){ref-type="fig"}).

HIF-1α Controls Tumor-Infiltrating Tregs' Migratory Capacity *In Vivo* {#S10}
----------------------------------------------------------------------

To determine whether this migratory perturbation is occurring *in vivo*, we sorted and expanded HIF-1α WT or HIF-1α KO Tregs, labeled with two different stable fluorescence tags and mixed at a 1:1 ratio before being injected intravenously (i.v.) into tumor-bearing mice ([Figure 7A](#F7){ref-type="fig"}). After 48 h, organs were harvested, and the ratio of HIF-1α WT:KO Tregs was assessed ([Figure 7B](#F7){ref-type="fig"}). While the ratios of Tregs in the spleen and draining lymph node (DLN) were 1:1 and 1:1.4, respectively, in the tumor, HIF-1α WT Tregs were 3.2-fold higher (p \< 0.001) than HIF-1α KO Tregs. We also pre-treated Tregs with DCA and performed the same competition assay, which also revealed reduced Treg infiltration into the tumor ([Figure S7C](#SD1){ref-type="supplementary-material"}). These data demonstrate a reduced infiltrative capability of Tregs deficient in HIF-1α.

Implantation of the murine syngeneic GL-261 astrocytoma model into HIF-1α WT and HIF-1α KO mice revealed a small but significant increase in animal survival in HIF-1α KO animals (p ⩽ 0.01), as shown in ([Figure 7C](#F7){ref-type="fig"}). Immune infiltrate analysis at 14 days after tumor implantation shows a specific decrease in the number of Foxp3^+^CD4^+^ T cells ([Figure 7D](#F7){ref-type="fig"}) in the tumor, with no observable changes in effector CD4^+^ or CD8^+^ T cell numbers ([Figure S7A](#SD1){ref-type="supplementary-material"}). Interestingly, reduction in Treg numbers is only apparent in the CNS, suggesting that the influence of HIF-1α on Tregs is geographically related to the glioma. Measurement of known Treg chemokine receptors was unchanged on HIF-1α WT Tregs compared to HIF-1α KO Tregs ([Figure S7B](#SD1){ref-type="supplementary-material"}). Lastly, immunofluorescence of Foxp3^+^ T cell infiltrates after 2 weeks of tumor growth revealed a significant reduction in Treg numbers within the tumors of mice ([Figure 7E](#F7){ref-type="fig"}).

DISCUSSION {#S11}
==========

The microenvironment of glioma is harsh for the survival of cells, yet Tregs persist despite these challenges. The results of this study not only broaden our knowledge of Treg biology in the context of glioma but also reveal the competition between the migratory and functional needs of these specialized cells.

Perhaps the most well-known study on the function of HIF-1α and Tregs is by [@R9]. In this study, they show that HIF-1α is important for the function and survival of Tregs in inflamed tissues. Specifically, HIF-1α can bind to the Foxp3^+^ promoter, is induced by hypoxia, and can prevent colitis in an adoptive transfer model of HIF-1α deficiency ([@R9]). However, other studies suggest that HIF-1α is deleterious to Treg function. For example, other studies have shown that HIF-1α binds to Foxp3, degrading it ([@R11]), or that HIF-1α broadly downregulates Treg function ([@R20]). We believe that our study reconciles many of these observations.

First, we determined that HIF-1α KO Tregs suppress better than HIF-1α WT Tregs under hypoxia, a notion in line with studies that suggest that HIF-1α antagonizes Foxp3^+^ suppressive function ([@R20]; [@R21]). Our results confirm that the immune suppressive capabilities of Tregs require mitochondrial metabolism, which has also been previously suggested ([@R16]). Our data support this by showing that deficiency of HIF-1α prevents pyruvate from being shuttled to lactate production, resulting in overactive mitochondrial metabolism. The model also helps us understand previous studies suggesting that fatty acid metabolism is critical for Treg function. Many previous studies have suggested that exogenous lipids ([@R6]) and subsequent lipid oxidation are metabolically relevant for Tregs ([@R16]; [@R19]; [@R31]); however, HIF-1α KO Treg resistance to Eto treatment highlights that Treg dependence on lipids is context dependent. Indeed, under the context of hypoxia, Treg suppression is severely affected by the inhibition of lipid metabolism. Therefore, under hypoxic situations, HIF-1α does, indeed, inhibit Treg suppression, but the presence of FFA in the TME promotes their suppressive functionality.

Several decades-old studies initially highlighted the presence of FFAs in the glioblastoma microenvironment ([@R18]; [@R29]; [@R42]). Not only do our data agree with this, but it also appears that Tregs utilize this fuel in an environment in which few other substrates are available. Through several lines of evidence, we show that Tregs uptake more lipids and have the transportation machinery required for this uptake, which is in agreement with a very recent study showing that Tregs can utilize fatty acid metabolism as a complement to glycolysis ([@R37]). This then suggests that inhibition of fatty acid metabolism in the glioma microenvironment could stymie Treg function.

As Eto has been recently shown to have various effects independent of preventing lipid transport into mitochondria, verification using another inhibitor was critical to our study. By showing that inhibition of palmitate uptake, utilizing SSO, also inhibits Treg function, we are validating a core ideology of Treg suppressive function, the necessity of lipid metabolism. It also shows that Treg will, indeed, utilize exogenous fatty acids for their mitochondrial function and substantiates the framework of this study. The resistance of HIF-1α-deficient Tregs to both of these inhibitors provides essential evidence that hypoxic signaling is central to this metabolic decision.

Our study also elucidates the role that FA metabolism has on immunosuppression within the brain TME. This study provides evidence that a temporary change in lipid metabolism is enough to augment the immunosuppression of glioma. Other research has suggested that this mechanism is through the effects on cancer cells in the microenvironment, which, no doubt, can play a critical role in tumor progression ([@R5]; [@R27]). However, through the use of Rag-1 KO mice, which lack T cells and B cells, the survival effect is negated, suggesting that the immune function is critical to the survival effects of fatty acid oxidation inhibition.

Lastly, we show in our murine model of glioma that ablation of HIF-1α leads to enhanced animal survival due to the decrease in the migratory abilities of HIF-1α KO Tregs. A recent study suggests that glucokinase (GCK)-mediated glycolysis drives Treg migration, generating quick ATP for migratory processes ([@R24]). As HIF-1α activation promotes glycolytic processes over the import of pyruvate into the mitochondria for OXPHOS, our data show that HIF-1α is responsible for energizing the migration of Tregs.

This study demonstrates that hypoxia and HIF-1α interact to limit the suppressive function of Tregs; however, future work is critical to understand how other regulators of HIF-1α, such as mTORC1, contribute to Treg function or migration in brain tumors or how this pathway is controlled in Tregs compared to conventional T cell subsets. In summation, this study provides a clear picture in which HIF-1α can promote the migration of Tregs at the expense of immune suppression and that immune suppression under hypoxia prefers lipids for fuel. Future studies will need to determine whether we can promote the lipid oxidation phenotype of effector immune cells to thrive within CNS tumors, as was previously shown in a model of melanoma ([@R50]). We hope that the interrogation of any of these strategies may promote future therapies for this incurable disease.

STAR★METHODS {#S12}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S13}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Maciej Lesniak (<maciej.lesniak@northwestern.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S14}
--------------------------------------

### Mice {#S15}

C57BL/6 (WT), C57BL/6-Foxp3-YFP-CRE, RAG1^0/0^, C57BL/6-HIF-1α^flox/flox^ were obtained and bred from Jackson Laboratories and housed in Northwestern University animal facility at the Center for Comparative Medicine (CCM). Foxp3-YFP-CRE was crossed with C57BL/6 HIF-1α-flox to generate Treg specific knockout of HIF-1α. Crossing was verified with genotyping using primers designed and validated by Jackson Laboratories. Mice aged 6--10 weeks were used for all experiments. Animal survival was conducted following endpoint protocols outlined in our approved animal protocols by CCM. All experimental protocols followed NIH guidelines and were approved by the institutional animal care and use committees (IACUC) at Northwestern University. For any and all experiments using HIF-1α-Treg KO mice, we used age and gender matched Foxp3-YFP-CRE mice as WT controls throughout the manuscript. Both male and female mice were used for all experiments. In any primary cell cultures or assays, controls were age matched and sex matched for every experiment.

### Cells {#S16}

The GL-261 glioma cell lines were directly purchased from NCI and cultured in DMEM (Fisher, Hampton, NJ), 10% FBS (Hyclone) with penicillin/streptomycin (Invitrogen). GL-261 is a malignant glioma cell line that is syngeneic to C57BL/6 mice (the sex of the originating tumor is Male) and was administered via intracranial injection using a stereotactic apparatus at a concentration of 2×10^5^ GL-261 cells in 2.5 μL PBS (Sigma, St Louis, MI) at 6--10 weeks of age as described previously ([@R33]). Cell Lines GBM6 (Age/Sex:65/Male) and GBM12 (Age/Sex:85/Male) were obtained from C. David James Laboratory, and MES83 (Age/Sex:unknown/Female) were obtained from Ichiro Nakano, University of Alabama at Birmingham through Shi-Yuan Cheng at Northwestern University. Human cell lines were cultured in 1% FBS/DMEM. For *in-vitro* assays of proliferation, dye uptake, and cell death all cells were plated at a density of 5×10^4^ per well in a 96 well plate for all assays.

METHOD DETAILS {#S17}
--------------

### Treg culture isolation {#S18}

Splenocytes were harvested into single cell suspension from C57BL/6-Foxp3-YFP-CRE or C57BL/6-Foxp3-YFP-CRE-HIF-1α KO age and gender matched mice. Pre-enrichment of T cells was performed using the Magni-sort T cell enrichment kit (Fisher) including anti-CD8 biotin for depletion (Biolegend). Enriched cells were then sorted using a BD FACS Aria II cell sorter (Becton Dickinson, Franklin Lakes, NJ) using CD4-APC and Foxp3^+^YFP^+^ expression, then expanded with Dynabeads (Invitrogen) T cell expander beads and 2000U/ml recombinant IL-2 (Peprotech). For hypoxia treatment, Tregs from control or HIF-1α-Treg KO mice were plated overnight in 1% O~2~ or 21% O~2~ for gene expression or flux analysis. In experiment with flux analyses, drugs were added immediately before assay initiation. Sorted and expanded Tregs were used for suppressor assays, extracellular flux analyses, and migration assays are as described below.

### In-vitro T cell suppressor/proliferation assays {#S19}

For suppressor assays, Tregs were treated with inhibitors for 24 hours before being washed 3X and subsequently co-cultured (at decreasing ratios) with freshly-isolated, CTV-labeled CD8^+^ T cells, Dynabeads (1:3 bead/T cell ratio), and 30U/ml of recombinant IL-2 (Peprotech) for 72 hours. After 72 hours (96 hours for 1% O~2~ suppressors), T cells were harvested, labeled with APC-efluor780 viability dye (Ebioscience), followed by staining with appropriate flow cytometry antibodies immediately before flow cytometric analysis.

### Flow cytometry analysis {#S20}

For *in-vitro* studies the following flow cytometry panel was used in conjunction with CTV and viability dye: anti-CD3 Alexa700, CD4 PE-Cy7, CD8 APC, CD44 PE all at a 1:200 dilution purchased from Biolegend. For *in-vivo* and *ex-vivo* studies, the following flow cytometry panel was used: anti-CD3 PE-Cy7, CD4 Pacific Blue, CD8 APC, CD44 PE, and anti-CD25 Alexa 700 all at a 1:200 dilution (except anti-CD25 at a 1:50 dilution) and were purchased from Biolegend. Endogenous Foxp3 expression was detected via eYFP fluorescence (or re-stained with anti-Foxp3 Efluor-450 clone FJK-16 s for any overnight staining (Fisher)), all acquisition was performed using a BD Fortessa flow cytometer. For surface FA transporter measurement, anti-CD36-APC (Biolegend), SLC27A1 (sigma), and SLC27A4 was purchased from Abcam (Cambridge, UK), followed by secondary goat anti-rabbit IgG Alexa-647 (Jackson Immunoresearch, West Grove, PA). Proliferation was analyzed using both FACS DIVA software as well as FlowJo software to determine expansion indexes.

### Immunofluorescence {#S21}

After 14 days tumor engraftment, tumors from WT and KO mice were flash frozen in OCT (Fisher) and sectioned into 8μm slices using a CM1860 cryostat (Leica, Wetzlar, Germany). Sections were fixed in pre-chilled acetone then stained overnight at 4°C with 1:100 Foxp3-Biotin (Ebioscience) and Laminin-Alexa Fluor 647 1:500 (Novus, Littleton, CO) in antibody staining buffer - 0.5% Triton X-100 and 1% BSA (Sigma) in TBS (Boston Bioproducts, Ashland, MA). The following day, Streptavidin Alexa Fluor-488 (Fisher) was added for 2 hours at RT, washed, and mounted using Fluoroshield with DAPI (Sigma). Images were taken with a Leica DMi8 microscope with a 20X objective. Data was processed and quantified using imageJ.

### Extracellular flux analysis {#S22}

Metabolic rate of Tregs was determined via the Agilent Seahorse mitochondrial stress test assay modified with an initial palmitate injection (Santa Clara, CA). Briefly, expanded Tregs were cultured for 4 hours in substrate-limited medium (Kreb's/HEPES Buffer) before being adhered to a Agilent Seahorse XF96 cell culture microplate with Cell Tak (Corning, Corning, NY) at a density of2.5×10^5^ Tregs/well which were then washed with fatty acid media (the day of the assay in a 96-well assay plate)([@R46]). The stress test for Tregs was performed by injection of Palmitate-BSA before the injections of all standardized reagents for the mitochondrial stress test as described in the protocol. CCL22 (Peprotech) was injected at a final concentration of 100 ng/ml to measure ECAR over time. All reagents for the mitochondrial stress test, including Palmitate-BSA and BSA controls, were purchased from Agilent.

### Migration assays {#S23}

To determine the *in-vitro* migration of Tregs, expanded Tregs were cultured overnight in 5% reduced serum RPMI before being plated at a density of 2.5×10^5^ Tregs/well in the top chamber of 3μm transwell inserts (Corning). The bottom wells were either seeded with 5×10^4^ GL-261 overnight or plated with 5% FBS RPMI supplemented with 100ng/ml recombinant murine CCL22 (Peprotech). Tregs were allowed to migrate overnight at 1% O~2~ before migration was assessed. Both cells in the top chamber and bottom chamber were manually counted by a blinded researcher (W.K.P.) to validate migration. For *in-vivo* migration of Tregs, expanded Tregs were labeled with eBioscience Cell Proliferation Dye eFluor 450 (HIF-1α WT Tregs) or eFluor 670 (HIF-1α KO Tregs), mixed at a 1:1 ratio, and injected *i.v*. (2.5×10^6^ of each Treg) into GL-261 tumor-bearing mice one week after injection. After 48 hours, cells were isolated from brains, spleen, and DLNs of mice, stained with markers for CD4-Percp-Cy5.5 and CD45-PE, and ratios of labeled Tregs were analyzed.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S24}
---------------------------------------

Statistical significance across two group was determined using two-tailed unpaired Student's t test performed on [Figures 1A](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"}--[2B](#F2){ref-type="fig"} (left), [2D](#F2){ref-type="fig"}, [3D](#F3){ref-type="fig"}, [3G](#F3){ref-type="fig"}, [4D](#F4){ref-type="fig"}, [5B](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}, [6D](#F6){ref-type="fig"}--[6G](#F6){ref-type="fig"}, [7D](#F7){ref-type="fig"}--[7E](#F7){ref-type="fig"}, [S1](#SD1){ref-type="supplementary-material"}, [S2](#SD1){ref-type="supplementary-material"}, [S5](#SD1){ref-type="supplementary-material"}, and [S7A](#SD1){ref-type="supplementary-material"}--[S7B](#SD1){ref-type="supplementary-material"}. One-way ANOVA with Tukey's post hoc was performed on [Figures 1B](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"} (right), [2C](#F2){ref-type="fig"}, [3H](#F3){ref-type="fig"}, [3I](#F3){ref-type="fig"}, [4B](#F4){ref-type="fig"}--[4D](#F4){ref-type="fig"}, [4F](#F4){ref-type="fig"}, [6B](#F6){ref-type="fig"}--[6C](#F6){ref-type="fig"}, [7B](#F7){ref-type="fig"} (right), [S3A](#SD1){ref-type="supplementary-material"}--[S3B](#SD1){ref-type="supplementary-material"}, [S4B](#SD1){ref-type="supplementary-material"}, [S4D](#SD1){ref-type="supplementary-material"}, [S4F](#SD1){ref-type="supplementary-material"}, [S6A](#SD1){ref-type="supplementary-material"}--[S6B](#SD1){ref-type="supplementary-material"}, and [S7C](#SD1){ref-type="supplementary-material"} for comparisons of 3 or more groups. Kaplan Meier curves were generated and the Log rank test was performed for analysis of *in-vivo* survival rate ([Figure 5A](#F5){ref-type="fig"}, [5C](#F5){ref-type="fig"}, and [7C](#F7){ref-type="fig"}). p values were calculated in Prism software (Graphpad, San Diego, CA) and the significance are as stated in the figure legends. Error bars shown as ± the Standard Error of the Mean (SEM) for all figures. Immunofluorescence images were processed in ImageJ

DATA AND SOFTWARE AVAILABILITY {#S26}
------------------------------

Raw and analyzed data has been submitted to the Mendeley database and is available using following doi: <https://doi.org/10.17632/k8z9vbmddc.1> Direct weblink to Mendeley datasets: <https://data.mendeley.com/datasets/k8z9vbmddc/1>
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![Deficiency of HIF-1α Promotes the Mitochondrial Utilization of Glucose under Hypoxia\
(A and B) FACS-sorted and expanded Tregs from C57BL/6 Foxp3-YFP-Cre mice (HIF-1α WT) or Foxp3-YFP-Cre HIF-1α^flox/flox^ mice (HIF-1α KO) were placed under normoxia or hypoxia overnight before being adhered to microplates, and oxygen consumption rate (OCR) was determined over time (A) and analyzed as bar graphs (B). A modified mitochondrial stress test was performed with an initial palmitate injection to determine palmitate-induced respiration and mitochondrial function of Tregs. Data were analyzed using Wave software from Agilent. n = 5 wells per condition were analyzed, representative of two independent experiments.\
Statistics were calculated as percent positive population ± SEM. One-way ANOVA followed by Tukey's post hoc analysis was used to calculate significance. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant.\
See also [Figures S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1526214-f0002){#F1}

![HIF-1α KO Tregs Suppress CD8^+^ T Cell Proliferation Better than HIF-1α WT Tregs under Hypoxia due to Enhanced Glucose Oxidation\
(A and B) Sorted and expanded Tregs were plated with proliferation-dye-labeled CD8^+^ T cells at decreasing ratios to determine their suppressive capability under (A) 21% O~2~ and (B) 1% O~2~. After 72 h, CD8^+^ T cell proliferation was analyzed. An n of 3 wells per ratio was analyzed, representative of three independent experiments.\
(C) Sorted and expanded Tregs were pre-treated with UK5099 (10 μm) or vehicle control for 24 h before a suppressor assay was run under 1% O~2~. After 72 h, percent proliferation and expansion indexes were determined via flow cytometry. An n of 3 per condition was analyzed, from two independent experiments.\
(D) Sorted and expanded Tregs were pretreated with 1 mM DCA treatment overnight before suppressor assays were performed under 1% O~2~.\
Statistics were calculated as percent positive population ± SEM. Unpaired t test analysis was used to calculate significance. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant.](nihms-1526214-f0003){#F2}

![Inhibition of Either Lipid Uptake or Lipid Oxidation Prevents Immunosuppressive Capabilities of Regulatory T Cells\
(A) Sorted and expanded Tregs were cultured for 72 h in the presence of the fatty acid oxidation inhibitor etomoxir (200 μM) or the fatty acid uptake inhibitor SSO (200 μM), and the expression of various Tregs markers was assessed via flow cytometry.\
(B and E) Sorted Tregs were cultured for 72 h in the presence of etomoxir (Eto; 200 μM; B) or SSO (200 μM; E), and Foxp3 retention was determined.\
(C and D) Percent CD8 T cell proliferation with co-culture of Eto pre-treated Tregs shown as a histogram (C) and analyzed as bar graphs with reducing Treg ratios (D) that were enumerated via flow cytometry.\
(F and G) Percent CD8 T cell proliferation with co-culture of SSO pre-treated Tregs shown as a histogram (F) and analyzed as bar graphs with reducing Treg ratios (G) that were enumerated via flow cytometry.\
(H and I) Sorted and expanded WT or HIF-1α KO Tregs were pretreated with (H) Eto (200 μM) or (I) SSO (200 μM) for 24 h before a suppressor assay was run under 1% O~2~. After 72 h, expansion indexes were determined via flow cytometry.\
Flow cytometry statistics were calculated and shown as percent positive or MFI ± SEM; n = 5 per group in (A), and n = 3 per ratio in (B)--(I), representative of 2--3 independent experiments. A one-way ANOVA followed by Tukey's post hoc analysis was used to calculate significance. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1526214-f0004){#F3}

![Regulatory T Cells Utilize Lipids for Their Mitochondrial Metabolism under Hypoxia and Prefer Lipids for Metabolism within Glioma\
(A and B) Flow-cytometry-sorted and expanded HIF-1α WT or HIF-1α KO Tregs were placed under 1% O~2~ overnight before being adhered to microplates, and extracellular flux analysis was performed over time (A) and analyzed as bar graphs (B). Eto treatment (20 μm) was added immediately before assay to determine reliance on lipids for mitochondrial metabolism.\
(C--F) Wild-type C57/Bl6 mice were implanted with 4 × 10^5^ GL-261 astrocytoma cells, and after 2 weeks of tumor growth, T cell expression of surface fatty acid transporters was analyzed via flow cytometry.\
(C) Percent palmitic acid uptake and MFI of conventional CD4^+^, CD8^+^, and Treg subsets.\
(D) Percent 2-NDBG and MFI of 2-NBDG conventional CD4^+^, CD8^+^, and Treg subsets.\
(E) Tumor interstitial fluid was obtained from either the tumor hemisphere or the non-tumor hemisphere of mice, and FFA content was measured via colorimetric readout.\
(F) Data show the expression of fatty acid transporters CD36, SLC27A1, and SLC27A4 across different T cell subsets in the brains, DLN, and spleens of tumor-bearing mice (left); representative flow cytometry plots are shown on the right.\
Statistics were calculated as percent positive population ± SEM. Data in (A) and (B) were analyzed using Wave software from Agilent. Statistics were calculated as percent positive population ± SEM, n = 5 per group; results are representative of three experiments in (A) and (B) and two experiments in (C)--(F). One-way ANOVA followed by Tukey's post hoc analysis was used to calculate significance. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1526214-f0005){#F4}

![*In Vivo* Treatment of Eto Causes a Survival Benefit in Immunocompetent Mice\
(A) Survival of WT or immunodeficient Rag^0/0^ mice implanted with 4 × 10^5^ GL-261 and treated with intracranial Eto administration beginning at day 7 after tumor implantation.\
(B) Quantification of Tregs and their ratios to other T cell subsets 48 hr after Eto treatment (day 9).\
(C) Survival of mice injected i.p. with 30 mg/kg Eto.\
(D) Flow-cytometric analysis of Treg infiltration and their ratios to other T cell subsets 48 h after second Eto treatment (9 days). Survival curves are from at least 7 mice per group from two independent experiments; statistical significance was calculated using log-rank analysis.\
Flow cytometry statistics were calculated and are indicated as percent positive population ± SEM; n = 5 per group, representative of two independent experiments in (B) and one experiment in (D). Unpaired t test analysis was used to calculate significance. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant. See also [Figures S5](#SD1){ref-type="supplementary-material"} and [S6A](#SD1){ref-type="supplementary-material"}.](nihms-1526214-f0006){#F5}

![Deficiency of HIF-1α Inhibits Glycolytic Metabolism of Tregs, Resulting in Reduced *In Vitro* Migration\
(A and B) FACS-sorted and expanded HIF-1α WT or HIF-1α KO Tregs were placed under 21% O~2~ or 1% O~2~ overnight before being adhered to microplates, and extracellular acidification rate (ECAR) was determined over time (A) and analyzed as bar graphs (B).\
(C) FACS-sorted and expanded HIF-1α WT or HIF-1α KO Tregs were put under 21% O~2~ or 1% O~2~ overnight, and qRT-PCR was performed to determine the expression of PDK1 and LDHA.\
(D and E) Sorted and expanded HIF-1α WT Tregs were treated with 1 mM DCA overnight before being adhered to microplates, and metabolic flux was determined over time (D) and analyzed as bar graphs (E). Data were analyzed using Wave software from Agilent.\
In (A), (B), (D), and (E), an n of 5 wells per condition was analyzed, representative of two independent experiments. In (C), an n of 3 per condition was analyzed from three independent experiments.\
(F) Sorted and expanded Tregs from HIF-1α WT or HIF-1α KO mice were plated in Transwell inserts to measure their migration toward the chemokine CCL22 or GL-261 tumor cells under 1% O~2~.\
(G) FACS-sorted and expanded HIF-1α WT or HIF-1α KO Tregs were injected with CCL22, and change in ECAR was measured.\
In (F), statistics were calculated as percent migration ± SEM. In (B) and (C), one-way ANOVA followed by Tukey's post hoc analysis was used to calculate significance. In (D) and (E), unpaired t test analysis was used to calculate significance. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant.\
See also [Figure S6B](#SD1){ref-type="supplementary-material"}.](nihms-1526214-f0007){#F6}

![Conditional Knockout of HIF-1α in Foxp3^+^ T Cells Inhibits Migration of Tregs to Brain Tumors *In Vivo*\
(A) To test Treg migration *in vivo*, splenic-sorted and expanded Tregs were co-labeled with eFluor 450 (HIF-1α WT) and eFluor 670 (HIF-1α KO) cell proliferation dyes and injected i.v. at a 1:1 ratio into mice harboring GL-261.\
(B) After 48 h, the brain, spleen, and DLN of mice injected with Tregs were isolated, and the ratio of control to HIF-1α KO Tregs was determined.\
(C) HIF-1α WT or HIF-1α KO mice were implanted with 4 × 10^5^ GL-261 astrocytoma cells, and overall survival was determined.\
(D) After 2 weeks of tumor growth, Treg abundance was analyzed via flow cytometry.\
(E) Abundance of Foxp3^+^ cells from tumor-bearing mice was quantified in tissue sections. Kaplan-Meier curves are n = 7 per group from two independent experiments, and significance was calculated using log-rank analysis.\
Flow cytometry statistics shown as percent positive population ± SEM; n = 5 per group, representative of two experiments. In (B), the ratios of WT/HIF-1α KO Tregs were indicated as mean ± SEM. In (E), 3--5 fields per section were quantified for Foxp3^+^DAPI^+^ nuclei. n = 3 mice per group. Unpaired t test analysis was used to calculate significance. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant.\
See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms-1526214-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                             SOURCE                                                                                                IDENTIFIER
  ----------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Antibodies                                                                                                                                            
  Anti-CD3 Alexa Fluor 700                        Biolegend                                                                                             Cat\#100216; RRID:AB_493697
  Anti-CD3 PE-Cy7                                 Biolegend                                                                                             Cat\#100220; RRID:AB_1732057
  Anti-CD4 APC                                    Biolegend                                                                                             Cat\#100516; RRID:AB_312719
  Anti-CD4 Biotin                                 Biolegend                                                                                             Cat\#100508; RRID:AB_312711
  Anti-CD4 Percp-Cy5.5                            Biolegend                                                                                             Cat\#100540; RRID:AB_893326
  Anti-CD4 PE-Cy7                                 Biolegend                                                                                             Cat\#100528; RRID:AB_312729
  Anti-CD4 Pacific blue                           Biolegend                                                                                             Cat\#100531; RRID:AB_493374
  Anti-CD45 PE                                    Biolegend                                                                                             Cat\#103106; RRID:AB_312971
  Anti-CD8 Biotin                                 Biolegend                                                                                             Cat\#100714; RRID:AB_312753
  Anti-CD8 APC                                    Biolegend                                                                                             Cat\#100712; RRID:AB_312751
  Anti-CD8 BV605                                  Biolegend                                                                                             Cat\#100744; RRID:AB_2562609
  Anti-CD44 PE                                    Biolegend                                                                                             Cat\#103008; RRID:AB_312959
  Anti-CD25 Alexa 700                             Biolegend                                                                                             Cat\#102024; RRID:AB_493709
  Anti-CD36 APC                                   Biolegend                                                                                             Cat\#102611; RRID:AB_571994
  Anti-CTLA4 PE                                   Biolegend                                                                                             Cat\#106306; RRID:AB_313255
  Anti-Granzyme B Alexa 647                       Biolegend                                                                                             Cat\#515406; RRID:AB_2566333
  Anti-NRP1 PE-Cy7                                Biolegend                                                                                             Cat\#145211; RRID:AB_2562359
  Anti-CD39 Alexa 647                             Biolegend                                                                                             Cat\#143807; RRID:AB_2563977
  Anti-SLC27A1                                    Sigma                                                                                                 Cat\#SAB1402095; RRID:AB_10609989
  Anti-SLC27A4                                    Abeam                                                                                                 Cat\#ab200353; RRID:AB_2716563
  Anti-Foxp3 EFIuor 450                           Fisher                                                                                                Cat\#48--5773--82; RRID:AB_1518812
  Anti-Foxp3 Biotin                               Fisher                                                                                                Cat\#13--5773--82; RRID:AB_763540
  Goat anti rabbit Alexa 647                      Fisher                                                                                                Cat\#A-21236; RRID:AB_141725
  Streptavidin Alexa 488                          Jackson Immunoresearch                                                                                Cat\#016--540--084; RRID:AB_2337249
  Anti-Laminin Alexa 647                          Novus                                                                                                 Cat\#NB300--144AF647
  Bacterial and Virus Strains                                                                                                                           
  Biological Samples                                                                                                                                    N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                                                         
  Sulfo-N-suooinimidyl Oleate                     Cayman                                                                                                Cat\#11211
  Etomoxir Sodium Salt                            MedChem Express                                                                                       Cat\#HY-50202A
  Palmitate-BSA                                   Agilent                                                                                               Cat\#102720--100
  Sodium Dichloroacetate                          Sigma                                                                                                 Cat\#347795
  Cell Trace Violet                               Fisher                                                                                                Cat\#C34557
  Fluoroshield with DAPI                          Sigma                                                                                                 Cat\#F6057--20ML
  UK5099                                          Cayman                                                                                                Cat\#16980
  Quantum Dot 605 - Palmitate conjugate           In lab                                                                                                N/A
  Dynabeads T cell Expander                       Fisher                                                                                                Cat\#11452D
  Recombinant IL-2                                Peprotech                                                                                             Cat\#212--12
  Recombinant TGF-β                               Peprotech                                                                                             Cat\#100--21
  Recombinant CCL22                               Peprotech                                                                                             Cat\#250--23
  2-NBDG                                          Fisher                                                                                                Cat\#N13195
  Cell Proliferation Dye eFluor 450               Fisher                                                                                                Cat\#65--0842--90
  Cell Proliferation Dye eFluor 670               Fisher                                                                                                Cat\#65--0840--85
  Cel Tak                                         Fisher                                                                                                Cat\#CB-40240
  Critical Commercial Assays                                                                                                                            
  MitoStress Test                                 Agilent                                                                                               Cat\#103015--100
  Xfe96 Flux Paks                                 Agilent                                                                                               Cat\#102416--100
  Murine T cell Magnisort Enrichment kit          Fisher                                                                                                Cat\#8804--6820--74
  Deposited Data                                                                                                                                        
  Raw and Analyzed data                           Mendeley                                                                                              <https://data.mendeley.com/datasets/k8z9vbmddc/1>
  Experimental Models: Cell Lines                                                                                                                       
  Murine glioma GL-261 Sex: M                     NCI                                                                                                   DTP, DCTD TUMOR REPOSITORY RRID:CVCL_Y003
  GBM6 Age/Sex:65/M                               C. David James, Northwestern University                                                               N/A
  GBM12 Age/Sex:68/M                              C. David James, Northwestern University                                                               N/A
  MES83 Age/Sex: Unknown/F                        from Ichiro Nakano, University of Alabama at Birmingham and Shi-Yuan Cheng, Northwestern University   N/A
  Experimental Models: Organisms/Strains                                                                                                                
  MOUSE: C57 BI/6                                 Jackson                                                                                               Cat\#000664; RRID:IMSR_JAX:000664
  MOUSE: Foxp3-^YFP--CRE^                         Jackson                                                                                               Cat\#016959; RRID:IMSR_JAX:016959
  MOUSE: Foxp3-Hif1a-^fl/fl^                      Jackson                                                                                               Cat\#007561; RRID:IMSR_JAX:007561
  MOUSE: Foxp3-^YFP--CRE^ × Hif1a-^fl/fl^         This Paper                                                                                            N/A
  MOUSE: Rag1^0/0^                                Jackson                                                                                               Cat\#002216; RRID:IMSR_JAX:002216
  Oligonuoleotides                                                                                                                                      
  β-Actin Forward: TTGCTGACAGGATG CAGAAG          Purchased: IDT                                                                                        Design: [ncbi.nlm.nih.gov/tools/primer-blast/](http://ncbi.nlm.nih.gov/tools/primer-blast/)
  β-Actin Reverse: ACATCTGCTGGAAG GTGGAC          Purchased: IDT                                                                                        Design: [ncbi.nlm.nih.gov/tools/primer-blast/](http://ncbi.nlm.nih.gov/tools/primer-blast/)
  PDK1 Forward: GGACTTCGGGTCAGT GAATGC            Purchased: IDT                                                                                        [https://pga.mgh.harvard.edu](https://pga.mgh.harvard.edu/) PrimerBank ID: 27369966a1
  PDK1 Reverse: TCCTGAGAAGATTGT CGGGGA            Purchased: IDT                                                                                        [https://pga.mgh.harvard.edu](https://pga.mgh.harvard.edu/) PrimerBank ID: 27369966a1
  LDHA Forward: TGTCTCCAGCAAAGA CTACTGT           Purchased: IDT                                                                                        [https://pga.mgh.harvard.edu](https://pga.mgh.harvard.edu/) PrimerBank ID: 6754524a1
  LDHA Reverse: GACTGTACTTGACAAT GTTGGGA          Purchased: IDT                                                                                        [https://pga.mgh.harvard.edu](https://pga.mgh.harvard.edu/) PrimerBank ID: 6754524a1
  Software and Algorithms                                                                                                                               
  Prism                                           Graphpad                                                                                              [www.graphpad.com](http://www.graphpad.com/); RRID:SCR_002798
  Facs Diva                                       BD                                                                                                    [www.bdbiosciences.com](http://www.bdbiosciences.com)
  Excel                                           Microsoft                                                                                             [www.microsoft.com](http://www.microsoft.com/); RRID:SCR_016137
  FlowJo                                          Treestar                                                                                              [www.flowjo.com](http://www.flowjo.com/); RRID:SCR_008520
  Wave                                            Agilent                                                                                               [www.agilent.com](http://www.agilent.com/); RRID:SCR_014526
  ImageJ                                          NIH                                                                                                   [imagej.nih.gov/ij/](http://imagej.nih.gov/ij/); RRID:SCR_003070

###### Highlights

-   HIF-1α acts as a switch to promote Treg migration at the cost of immunosuppression

-   Glycolysis promotes Treg migration, while OXPHOS promotes Treg immunosuppression

-   Tregs catabolize free fatty acids for immunosuppression within hypoxic brain tumors
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